Cargando…

Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System

Ligelizumab is a highly potent, humanized IgG1, anti-IgE monoclonal antibody. To explore its optimal subcutaneous delivery, the pharmacokinetics (PK), pharmacodynamics (PD), and tolerability of ligelizumab from two Phase 1 studies in healthy volunteers (HVs) and four Phase 2 and 3 studies in patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Yan, Calonder, Claudio, Kirsilä, Tiina, Burciu, Alis, Tisu, Matjaz, Joubert, Yolandi, Laurent, Nathalie, Hua, Eva, Patekar, Manmath, Drollmann, Anton, Woessner, Ralph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535857/ https://www.ncbi.nlm.nih.gov/pubmed/37765235 http://dx.doi.org/10.3390/pharmaceutics15092266

Ejemplares similares

Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria
por: Giménez‐Arnau, Ana, et al.
Publicado: (2022)

Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients
por: Bruin, Gerard, et al.
Publicado: (2020)

Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria()
por: Metz, Martin, et al.
Publicado: (2022)

Ligelizumab treatment for severe asthma: learnings from the clinical development programme
por: Trischler, Jordis, et al.
Publicado: (2021)

Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects
por: Arm, J P, et al.
Publicado: (2014)

The rationale for development of ligelizumab in food allergy
por: Wood, Robert A., et al.
Publicado: (2022)

Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus
por: Struemper, Herbert, et al.
Publicado: (2017)

Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics
por: Li, Junfeng, et al.
Publicado: (2015)

The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
por: Umemura, Kazuo, et al.
Publicado: (2016)

Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers
por: Gillen, Michael, et al.
Publicado: (2016)

Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma
por: Wang, B, et al.
Publicado: (2017)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
por: Peterschmitt, M. Judith, et al.
Publicado: (2020)

IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms
por: Kuo, Be-Sheng, et al.
Publicado: (2022)

Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon(®) and Eprex(®) following a single subcutaneous administration in healthy male volunteers
por: Yoon, Sumin, et al.
Publicado: (2017)

Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers
por: Teng, Renli, et al.
Publicado: (2013)

Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
por: Yoon, Deok Y., et al.
Publicado: (2021)

Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers
por: Wang, Shining, et al.
Publicado: (2022)

Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
por: Tummala, Raj, et al.
Publicado: (2018)

Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers
por: Härtter, Sebastian, et al.
Publicado: (2012)

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers
por: Nagelschmitz, J, et al.
Publicado: (2014)

Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers
por: Lee, Jieon, et al.
Publicado: (2014)

Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization
por: Cao, G, et al.
Publicado: (2013)

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers
por: Hall, Jesse, et al.
Publicado: (2018)

Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers
por: Liu, Shijia, et al.
Publicado: (2017)

Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study
por: Abd‐Rahman, Azrin N., et al.
Publicado: (2020)

Population Pharmacokinetic/Pharmacodynamic Modeling of the Effect of Abrocitinib on QT Intervals in Healthy Volunteers
por: Wang, Xiaoxing, et al.
Publicado: (2022)

The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab
por: Gasser, Pascal, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes
por: Chang, Hsuan-Ping, et al.
Publicado: (2023)

Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers
por: Jiang, Ji, et al.
Publicado: (2014)

Comparative pharmacokinetic and pharmacodynamic evaluation of branded and generic formulations of meloxicam in healthy male volunteers
por: Tacca, Mario Del, et al.
Publicado: (2013)

Clinical Evaluation of Humira(®) Biosimilar ONS-3010 in Healthy Volunteers: Focus on Pharmacokinetics and Pharmacodynamics
por: Dillingh, Marlous R., et al.
Publicado: (2016)

Comparison of the Pharmacokinetic–Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers
por: Kim, Seokuee, et al.
Publicado: (2018)

Pharmacokinetic/pharmacodynamic modeling and simulation of dotinurad, a novel uricosuric agent, in healthy volunteers
por: Motoki, Keisuke, et al.
Publicado: (2019)

Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers
por: Al‐Karagholi, Mohammad Al‐Mahdi, et al.
Publicado: (2021)

Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis
por: Bruin, Gerard, et al.
Publicado: (2019)

Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers
por: García-García, Idrian, et al.
Publicado: (2016)

A Study of Potential Pharmacokinetic and Pharmacodynamic Interactions between Dextromethorphan/Quinidine and Memantine in Healthy Volunteers
por: Pope, Laura E., et al.
Publicado: (2012)

Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim
por: Desai, Kalpna, et al.
Publicado: (2016)

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
por: Choi, Chungam, et al.
Publicado: (2018)

A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers
por: Johansson, Susanne, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qu1q0s22f5s4geaov7ahe0hs5t